Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/232377
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells |
Autor: | Cash, Timothy P.; Alcalá, Sonia CSIC ORCID; Rico-Ferreira, María del Rosario; Hernández Encinas, María Elena CSIC; García, Jennifer; Albarrán, María Isabel; Valle, Sandra; Muñoz, Javier ; Martínez-González, Sonia; Blanco-Aparicio, Carmen; Pastor, Joaquín; Serrano, Manuel; Sainz, Bruno Jr. | Palabras clave: | Compound library Cancer stem cells Pancreatic ductal adenocarcinoma Lysosomal membrane permeabilization Patient-derived xenografts |
Fecha de publicación: | 4-jul-2020 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Cancers 12(7): 1790 (2020) | Resumen: | Despite significant efforts to improve pancreatic ductal adenocarcinoma (PDAC) clinical outcomes, overall survival remains dismal. The poor response to current therapies is partly due to the existence of pancreatic cancer stem cells (PaCSCs), which are efficient drivers of PDAC tumorigenesis, metastasis and relapse. To find new therapeutic agents that could efficiently kill PaCSCs, we screened a chemical library of 680 compounds for candidate small molecules with anti-CSC activity, and identified two compounds of a specific chemical series with potent activity in vitro and in vivo against patient-derived xenograft (PDX) cultures. The anti-CSC mechanism of action of this specific chemical series was found to rely on induction of lysosomal membrane permeabilization (LMP), which is likely associated with the increased lysosomal mass observed in PaCSCs. Using the well characterized LMP-inducer siramesine as a tool molecule, we show elimination of the PaCSC population in mice implanted with tumors from two PDX models. Collectively, our approach identified lysosomal disruption as a promising anti-CSC therapeutic strategy for PDAC. | Versión del editor: | http://dx.doi.org/10.3390/cancers12071790 | URI: | http://hdl.handle.net/10261/232377 | DOI: | 10.3390/cancers12071790 | E-ISSN: | 2072-6694 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Induction_Cash_PV_Art2020.pdf | 4,4 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
5
checked on 14-abr-2024
SCOPUSTM
Citations
6
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
5
checked on 28-feb-2024
Page view(s)
65
checked on 18-abr-2024
Download(s)
89
checked on 18-abr-2024